NCT00157092已完成1 期
A Phase 1B/2A Study to Evaluate the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency
Baxalta now part of Shire1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2004年3月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- Alpha 1-antitrypsin levels assessed from epithelial lining fluid (ELF) samples
研究概览
简要总结
The study was a Phase 1B/2A, uncontrolled, open-label, single-center study in individuals with congenital AAT (alpha 1-antitrypsin) deficiency. A baseline bronchoscopy with bronchoalveolar lavage (BAL) was performed 3 to a maximum of 4 weeks prior to the first administration of study drug. Fifteen eligible subjects were randomized to receive 1 of 3 dosing regimens of rAAT (100 mg daily, 100 mg twice daily, or 200 mg daily) administered via nebulization for 7 consecutive days. A post-treatment nadir BAL was obtained on study Day 8 (12 hours after last dose for subjects who receive drug therapy twice daily and 24 hours after the last dose for subjects who receive study product daily). BALs were conducted in the same lung lobe/segment. Follow-up visits took place on Day 15 and Day 36.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed Informed Consent
- •Male or female 18 years of age or older
- •Documented, endogenous plasma AAT levels < 11 µM (< 80 mg/dL), either obtained from the medical history or, if not documented, plasma AAT measured after 28 day washout of any prior replacement therapy
- •Forced expiratory volume at 1 second (FEV1) that is >= 50% of predicted, measured 30 minutes after a short-acting inhaled bronchodilator
- •Arterial oxygen percent saturation (SaO2, measured using room air) within the normal limits for the individual study site
- •For subjects receiving an inhaled corticosteroid, inhaled or oral β-2 agonist (e.g., albuterol via metered dose inhaler [MDI]) or inhaled anticholinergic bronchodilator (e.g., ipratropium bromide), or oral PDE (phosphodiesterase) inhibitor, treatment on a stable dose for at least 14 days prior to enrollment
- •For any female of childbearing potential, a negative urine test for pregnancy within 3 days prior to enrollment and agreement to employ adequate birth control measures for the duration of the study
- •No clinically significant abnormalities detected on a 12-lead electrocardiogram (ECG) performed at the screening visit
- •Laboratory results obtained at the screening visit, meeting the following criteria:
- •Serum aspartate transaminase (AST) and alanine transaminase (ALT) <= 2 times upper limit of normal range (ULN)
- •Serum total bilirubin <= 2 times ULN
- •< 2+ proteinuria on urine dipstick
- •Serum creatinine <= 1.5 times ULN
- •Absolute neutrophil count >= 1500 cells/mm3
- •Hemoglobin >= 10.0 g/dL
- •Platelet count >= 100,000/mm3
排除标准
- •Clinically significant pulmonary impairment, other than emphysema and/or chronic bronchitis
- •Moderate to severe bronchiectasis
- •Clinically significant cardiac, hemostatic, or neurologic impairment, or other significant medical condition that, in the opinion of the investigator, would affect subject safety or compliance
- •Psychiatric or cognitive disturbance or illness, or recreational drug/alcohol use that, in the opinion of the investigator, would affect subject safety or compliance
- •Acute exacerbation of emphysema within 28 days prior to the screening visit
- •Pregnancy or lactation
- •Known history of allergy to yeast products
- •Medical history precluding the use of epinephrine or other rescue medication for treatment of anaphylaxis
- •Prior history of adverse reactions to the local anesthetic, sedative, BAL procedure, or pre-medication employed at the study center
- •Use of oral or parenteral glucocorticosteroids, or alpha 1-antitrypsin replacement therapy within 28 days prior to baseline BAL, or any use planned during the study. However, the subject may enroll provided that a) consent is given to undergo a 28-day washout of the replacement or steroid therapy, and b) no study procedures are done until the washout is completed.
- •Use of another investigational drug or investigational device within 28 days prior to baseline BAL
- •Any upper or lower respiratory infection within 28 days prior to baseline BAL
- •Having received a lung or liver transplant
结局指标
主要结局
Alpha 1-antitrypsin levels assessed from epithelial lining fluid (ELF) samples
时间窗: Day 8 after the first administration of study product
Alpha 1-antitrypsin levels assessed from epithelial lining fluid (ELF) samples
时间窗: Baseline (minimum of 3 to a maximum of 4 weeks prior to the first administration of study product).
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFactRespiratory Distress Syndrome in Premature InfantNCT03969992Aerogen Pharma Limited261
招募中
2 期
A clinical trial to evaluate the effect of low-dose atovaquone on the prevention of pneumocystis pneumonia in patients with rheumatic diseasesRheumatic DiseasesJPRN-jRCTs031210557Furuta Syunsuke50
Unknown
1 期
Study to Nivolumab Following Preoperative ChemoradiotherapyCancer of RectumNCT02948348Takayuki Yoshino90
尚未招募
2 期
A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011Advanced Breast CancerNCT06354114CSPC Ouyi Pharmaceutical Co., Ltd.80
终止
1 期
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)Epstein-Barr ViraemiaNasopharyngeal NeoplasmsEpstein-Barr Virus InfectionsNasopharyngeal CarcinomaEpstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)NCT03769467Atara Biotherapeutics12